Clinical trial of rebamipide combined with famotidine in the treatment of postoperative ulcer in patients with early gastric cancer
10.13699/j.cnki.1001-6821.2024.14.002
- VernacularTitle:瑞巴派特联合法莫替丁治疗早期胃癌术后溃疡患者临床研究
- Author:
Rui WANG
1
;
Duo LI
;
Zhao PENG
Author Information
1. 河北北方学院附属第一医院消化内科,河北张家口 075100
- Keywords:
rebarpide capsule;
famotidine tablet;
ulceration;
early gastric cancer;
gastric endoscopic mucosal dissection
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(14):2008-2012
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical value of rebabapide combined with famotidine in the treatment of postoperative ulcers in patients with early gastric cancer.Methods Postoperative ulcer patients with early gastric cancer were selected as the study objects,and were divided into control group and treatment group according to treatment plan using cohort method.Control group was orally treated with famotidine tablet 20 mg,bid;on the basis of the control group,the treatment group was orally treated with rebabapide capsule 0.1 g,tid,and both groups were treated for 4 weeks.The gastric mucosal morphological indexes,gastrointestinal hormone[vasoactive intestinal peptide(VIP),cholecystokinin(CCK),motilin(MTL),pepsinogen[pepsinogen Ⅰ(PG Ⅰ),pepsinogen Ⅱ(PG Ⅱ)]in the two groups were compared.Results There were 40 patients in the treatment group and control group.After treatment,the total clinical effective rate of the treatment group was 92.50％(37 cases/40 cases)and higher than that of the control group[75.00％(30 cases/40 cases)],and the difference was statistically significant(P＜0.05).After treatment,the scores of mucosal thickness in treatment group and control group were(0.22±0.08)and(0.51±0.10)points;the scores of inflammatory cell infiltration degree were(0.42±0.08)and(0.79±0.16)points;the scores of gland density were(0.80±0.12)and(1.16±0.27)points,respectively;mucosal morphology scores were 0.48±0.11 and 0.74±0.12;VIP were(16.78±2.49)and(19.46±3.02)ng·L-1;CCK were(55.38±58.47)and(71.48±10.38)ng·L-1,respectively;MTL were(82.19±14.52)and(97.68±11.58)pg·mL-1;PG Ⅰ were(168.74±17.42)and(136.78±15.44)ng·mL-1,respectively;PG Ⅱ were(16.42±2.50)and(20.58±3.79)ng·mL-1,respectively.Compared with control group,there were statistically significant differences in the above indexes in treatment groups(all P＜0.05).The incidence of adverse drug reactions in the treatment group was 15.00％(6 cases/40 cases)compared with 10.00％(4 cases/10 cases)in the control group,there was no statistical significance(P＞0.05).Conclusion Rebaptidine combined with famotidine is effective and safe in the treatment of postoperative ulcer patients with early gastric cancer.It can improve gastric mucosa morphological indexes,gastrointestinal hormones and pepsinogen.
